Netherlands-based Centrient Pharmaceuticals (Centrient), has started production at its new statins manufacturing unit in Toansa site in Punjab. The company will double its statins production capacity at its recently built second dedicated site. This will enable Centrient to meet the growing demand for its sustainably manufactured Atorvastatin and Rosuvastatin Active Pharmaceutical Ingredients (APIs).

“With the doubling of our production capacity, we demonstrate our commitment to maintain our leadership position in line with our strategy and to continue supporting our customers’ business growth. Guided by our brand promise of quality, reliability, and sustainability, Centrient’s rosuvastatin and atorvastatin offer superior performance in all three areas to the benefit of our customers and the environment”, says Frans Vlaar, Chief Commercial Officer at Centrient.

Groundbreaking of the new manufacturing unit started at the end of 2019 and commercial supplies from the new unit will start in mid-2021. With the new manufacturing line being operational and doubling the production capacity, Centrient will be even better positioned to secure supply, meeting the growing demand from customers. 

“We are proud that we have been able to complete this project in a timely way given the challenges of executing such a complex project amid the COVID pandemic,” says Jim McPherson, Chief Quality & Technical Operations Officer, Centrient. “It reinforces our absolute commitment to meet the expectations of our customers as a partner of choice - delivering reliable and secure supply using leading sustainable technologies. The facility incorporates design features that allow further improvements in GMP and energy utilisation, and enable greater automation for improved process control.”